cancerBiology180x110

Melanocytes Must Regain Primitive, Early Embryologic State to Develop Melanoma

Researchers working with the zebrafish melanoma model have determined that oncogene activation and crippling of tumor suppressors genes is not sufficient to transform melanocytes into melanoma cells. It is essential that the cells re-acquire primordial characteristics, as well. Continue reading

cancerBiology180x110

BET Bromodomain Inhibition in Prostate Cancer Treatment

BET bromodomain inhibitors are epigenetic regulators that act by repressing expression of oncogenes, including MYC and BCL-2, that are aberrantly highly expressed in many cancer cells, resulting in inhibited cell proliferation and induction of apoptotic cell death. Continue reading

cancerBiology180x110

Priority Review for Potent Novel Therapy for Chronic Lymphocytic Leukemia (CLL)

Venetoclax is a novel cancer therapy being developed by Roche and AbbVie. The U.S. FDA has accepted the New Drug Application and granted Priority Review and Breakthrough Therapy Designation for venetoclax for the treatment of people with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, including those with 17p deletion. Continue reading

cancerBiology180x110

Argos’ Metastatic Renal Cell Carcinoma Study Passes Independent Data Safety Monitoring Committee Second Interim Analysis

An independent data monitoring committee (IDMC) has recommended the continuation of Argos’ pivotal phase 3 ADAPT clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC) based on results of the committee’s second planned interim data analysis. The next planned interim analysis will be in 6 months. Continue reading

cancerBiology180x110

Biomarkers for Wnt activation Predict For HER-2(-) Breast Cancer and NSCLC Response to Vantictumab

OncoMed is developing several compounds that target Wnt and Notch pathways, which are important in cancer and cancer stem cell maintenance, survival, and proliferation. Biomarkers for response of Her-2-negative breast cancer and non-small cell lung cancer (NSCLC) following treatment with Vantictumab, anti-Wnt monoclonal antibody, have been developed. Continue reading

cancerBiology180x110

Tazemetostat Histone Methyltransferase Inhibitor for Hematologic and Solid Tumors

Tazemetostat is a small molecule inhibitor of EZH2 being developed by Epizyme, Inc for the treatment of patients with Non-Hodgkin Lymphoma, including germinal center and non-germinal center diffuse large B-cell lymphoma and follicular lymphoma, as well as genetically-defined solid tumors. In many human cancers, misregulated EZH2 enzyme activity results in misregulation of genes that control cell proliferation—without these control mechanisms, cancer cells are free to grow rapidly.  Continue reading

cancerBiology180x110

ROCA Ovarian Cancer Test for Early Detection

Each year, about 20,000 women in the United States get ovarian cancer. Among women in the United States, ovarian cancer is the eighth most common cancer and the fifth leading cause of cancer death, after lung and bronchus, breast, colorectal, and pancreatic cancers. In 2012 (the most recent year numbers are available)— 20,785 women in the United States were diagnosed with ovarian cancer, and 14,404 women in the United States died from ovarian cancer. Continue reading

cancerBiology180x110

Exploiting the Tumor Microenvironment – Threshold, Bioatla, Pfizer

Two companies announced news last week regarding their efforts to treat cancer by administering treatments that become activated by physiological conditions specific to the tumor microenvironment. Threshold Pharmaceuticals announced data from Phase III clinical trials of evophosphamide (TH-302), and BioAtla announced an antibody development deal with Pfizer. Continue reading

Second Multiple Myeloma Antibody Approved – Empliciti

Elotuzumab (Empliciti) is now the second monoclonal antibody (Mab) approved by the FDA for multiple myeloma (MM). Darzalex (daratumumab), the first Mab for MM, was approved by the FDA just 3 weeks ago. Continue reading